Xentuzumab clinical trials
Also written BI 836845.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses xentuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2014 (4)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2014 | 4 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 1
Studies
Open first, then newest update. How each study uses xentuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Phase I Trial of BI 836845 for Various Solid CancerCompletedPhase 1Boehringer IngelheimNCT01403974Written as BI 836845
- BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)CompletedPhase 1Boehringer IngelheimNCT02204072Written as BI 836845
- BI 836845 in Estrogen Receptor Positive Metastatic Breast CancerCompletedPhase 1Boehringer IngelheimNCT02123823Written as BI 836845
- Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour TypesCompletedPhase 1Boehringer IngelheimNCT01317420Written as BI 836845
- Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)CompletedPhase 1Boehringer IngelheimNCT02191891Written as Xentuzumab
- This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast CancerCompletedPhase 1Boehringer IngelheimNCT03099174Written as Xentuzumab
- Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid TumoursCompletedPhase 1Boehringer IngelheimNCT02145741Written as 750 milligram Xentuzumab
- The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has SpreadCompletedPhase 2Boehringer IngelheimNCT03659136Written as Xentuzumab
- IGF Inhibition With Xentuzumab Prior to Radical ProstatectomyCompletedEarly Phase 1University of OxfordNCT05110495Written as Xentuzumab
Codes
What other systems call xentuzumab · ClinicalTrials.gg INT006482
- MeSH (NLM) C588089xentuzumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) X86Z1O656GXENTUZUMABConfirmed FDA, NLM
- NCI Thesaurus C106118XentuzumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C588089 | xentuzumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | X86Z1O656G | XENTUZUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C106118 | Xentuzumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.